SL Science Holding Limited Reports Full Year 2025 Financial Results
SL Science Holding Limited (Nasdaq: SLBT) reported full-year 2025 results for the year ended Dec. 31, 2025. Net revenue fell 35% to about $2.20M from $3.36M, while net loss widened to about $3.82M from $1.19M. The company cited a Taiwan wholesale transition and higher G&A costs. It also said a $7.8M PIPE supported its Nasdaq Global Market listing after a business combination.
How this was made
The 30-second read
Why it matters
The release combines FY2025 financial deterioration (lower revenue, higher operating expenses, larger net loss, lower cash) with forward-looking execution items (FDA DMF status, CDMO tech transfer, and targeted IND-related timelines). It also references completion of a business combination and a $7.8M PIPE financing, which can affect perceived funding runway and risk appetite.
Market read
Traders get a concrete snapshot of FY2025 profitability/cash position plus a funding/transaction update that may influence near-term valuation and risk premium for a pre-IND biotech.
What to watch
Cash fell to ~$1.26M largely due to operating use and deferred offering costs; traders should separate one-time listing costs from ongoing burn and watch for the next concrete regulatory milestone (pre-IND/IND timing).
Background
SL Science is a Taiwan-headquartered biomedical company developing cellular and gene therapies, with an allogeneic Gamma Delta T (GDT) platform and a CD-19 Armed-T blood cancer program.
Ticker impact
SL Science reports FY2025 results showing net revenue of $2.20M (down 35%) and net loss of $3.82M (worse vs 2024).
Near-term sentiment likely pressured by higher net loss and lower cash, partially offset by the fresh Nasdaq/PIPE funding narrative.
The article provides concrete P&L and cash figures plus a capital-raising/transaction update; however, it lacks guidance or a same-day market catalyst beyond the disclosed milestones.
Market effects
Adds another datapoint on how pre-IND allogeneic cell-therapy developers are funding runway via PIPEs while shifting commercialization models.
Highlights Taiwan-headquartered biotech restructuring and FDA/TFDA regulatory preparation timelines.
Reinforces ongoing capital needs and regulatory execution risk across global cell-therapy pipelines.
Counterpoint
The revenue decline is attributed to a planned wholesale transition and lack of CD-19/GDT segment revenue, so the headline loss may overstate underlying clinical progress.
Key entities
- companySL Science Holding Limited
Reports FY2025 financial results and outlines pipeline/regulatory execution and funding milestones.
- venueNasdaq Global Market
Management states the company completed its Nasdaq listing as part of a business combination.
- capital_raisePIPE financing
Management cites $7.8 million PIPE financing to support growth and clinical operating needs.
- regulatoryFDA DMF (041080)
Company maintains an active U.S. FDA Drug Master File for its unmodified Vδ2+ GDT technology framework.
